DME Plant Set to Drive Balaji Amines' FY27 Growth

Balaji Amines is on the verge of commissioning a significant 100,000-tonne Dimethyl Ether (DME) plant, positioning the company to tap into the market for LPG alternatives in industrial and aerosol applications. This strategic expansion, alongside enhancements in its specialty chemicals division, is designed to fuel considerable volume growth by fiscal year 2027.

DME Plant Nears Launch

The new DME plant is projected to operate at 30-40% capacity in its first year. Pending regulatory approval, DME could serve as a viable substitute for LPG, opening up new revenue streams. This initiative aligns with Balaji Amines' strategy to replace imported products. The company's stock, valued at 10.5x EV/EBITDA for FY28, shows a 49.99% return in the past month and a 55.26% return over three months.

Expanding Specialty Chemical Offerings

Beyond DME, Balaji Amines is actively expanding its specialty chemical footprint. An upgraded acetonitrile plant is scheduled for completion in Q2 FY27, and a 5,000-tonne N-Methyl Morpholine (NMM) plant is planned for FY27. The Electronic Grade Battery Chemicals (DMC) plant is also expected to increase its output after initial delays. The company has allocated approximately Rs 280 crore for FY27 capital expenditure, with Rs 250 crore dedicated to its specialty business. This includes brownfield projects for Ethylene Diamine derivatives and a new Sodium Cyanide derivatives project.

Challenges and Competition Ahead

Despite optimistic growth plans, potential delays in project execution and regulatory approvals for the DME plant could impact market entry. Balaji Amines also faces stiff competition, particularly from Chinese manufacturers who offer lower prices, potentially affecting profit margins and plant utilization. While the company's balance sheet and operating cash flow remain strong, its trade receivables have increased. Competitors such as Alkyl Amines Chemicals Limited are also expanding, intensifying the rivalry in the aliphatic amines and specialty chemicals sectors. While Balaji Amines has historically outperformed Alkyl Amines in growth and profitability, Alkyl Amines maintains a leading position in certain product areas.

Future Outlook and Strategy

Management anticipates a 10-15% volume increase for FY27, with EBITDA margins expected to be between 22-23%. The company anticipates that rising costs for ammonia and methanol will be manageable through sourcing strategies. Balaji Amines' focus on import substitution and potential benefits from evolving global trade dynamics support its long-term strategy. The company's market capitalization was approximately ₹5,700 crore as of mid-May 2026.